Continuous glucose monitoring (CGM) now subsidised through NDSS

From 1st July, the Australian Government has announced that the Guardian Sensor 3 will be subsidised for all Australians living with Type 1 diabetes.



Medtronic welcomes the commitment made by the Coalition and Labor to enable expanded access to publicly funded Continuous Glucose Monitoring (CGM) for all patients with Type 1 Diabetes in Australia from 1 July 2022.

An extension of the CGM program is an important commitment that recognises the value of this technology in helping all patients with Type 1, and their Health Care Professionals, manage their condition. It addresses an access gap to this technology, and ensures those who are eligible under the existing CGM program do not have to revert to finger- pricking.

This announcement is a result of the many voices that advocate for Type 1 patients especially the Juvenile Diabetes Research Foundation, Diabetes Australia and the Australian Diabetes Society. Medtronic Australasia will work with Government to support the implementation of this important measure.

Do you want to learn more?

If you want to know more, please request a call to our team.